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Available online 3 February 2016The Genea023 human embryonic stem cell line was derived from a donated, fully commercially consented ART
blastocyst, through ICM outgrowth on inactivated feeders. The line showed pluripotent cell morphology and
genomic analysis veriﬁed a 46, XY karyotype andmale allele pattern through CGH and STR analysis. Pluripotency
of Genea023was demonstratedwith 85% of cells expressed Nanog, 98% Oct4, 55% Tra1-60 and 98% SSEA4, gave a
Pluritest Pluripotency score of 42.76, Novelty of 1.23, demonstrated Alkaline Phosphatase activity and tri-lineage
teratoma formation. The cell line was negative forMycoplasma and visible contamination.
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Cell line derivation
A fresh, blastocyst stage embryo was bisected and plated onto Mito-
mycin C inactivated human feeders (Detroit 551 HFF— 130,000/well in
4-well) in 20% KSR medium (Amit et al., 2000) with 50 ng/mL FGF
added fresh. CGH karyotyping and STR proﬁling was performed at the
ﬁrst cryobanking step from ICM outgrowths maintained on feeders. Al-
kaline Phosphatase staining and teratoma formation was performed
from feeders. Cells were then enzymatically passaged as single cells
in M2 pluripotent cell maintenance medium (Genea Biocells) and
CGH/karyotyping repeated, immunoﬂuorescent pluripotent marker
staining, pluritest and sterility testing performed.cense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Morphology and karyotype of Genea023. A) Alkaline Phosphatase activity (passage
14) on human inactivated feeders. B) Karyotypic analysis (passage 38) showing 46, XY
normal, male karyotype.
Table 1
CGH analysis summary; Genea023 (passage 15, 4 enzymatic) reporting a male cell line
with hemizygous loss of approximately 735 kb on chromosome 1.
CGH summary
Sample name Genea023p15_TE4
Date reported 8th October 2012
Hybridisation
balance
Balanced hybridization was observed for chromosomes
2–22 and sex chromosomes, relative to reference DNA
Unbalanced hybridization was observed for chromosome 1
Copy number change Loss, 1q21.2 approximately 735 kb
Interpretation Male cell line — a hemizygous loss of approximately 735 kb
on chromosome 1
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1. Karyotyping: Passage 38; For enrichment of metaphase cells, cellular
outgrowths were incubated with either 0.22 ng/mL colcemid
(Invitrogen) and 37.5 g/mL BrdU (Sigma) for 17–19 h or 5 ng/mL
colcemid for 2.5 h. Single cells were subsequently obtained using
Non-Enzymatic Cell Dissociation Solution (Sigma) and transferred
to Sydney IVF's (now Genea) diagnostic cytogenetics laboratory
for preparation of metaphase spreads and cytogenetic analysis by
G-banding. A minimum of 15 metaphase cells were examined, of
which a full karyotype or chromosome count was performed for 5
and 10 of the metaphases respectively.Table 2
STR proﬁle; Genea023 (passage 8) demonstrating male allele pattern.
D8S1179 D21S11 D7S820 CSF1PO D3S1358 TH01 D13S317
SIVF023p8 14 30,32.2 11,13 11,13 15,16 9.3 112. Comparative Genomic Hybridisation (CGH) based chromosomal
analysis: Passage 15; CGH was used to screen targeted regions
of the genome for gains and losses associated with chromosomal
imbalances such as aneuploidy, deletions and duplications. CGH
was performed using SurePrint G3 microarrays (8 × 60 K format)
which were scanned with the Agilent Scanner C and analysed
using Genomic Workbench Standard Edition 5.0 software (Agilent
Technologies).
3. DNA Proﬁling: Passage 8; DNA ‘ﬁngerprinting’ was performed using
the AmpFLSTR Identiﬁler PCR Ampliﬁcation Kit (Applied Biosystems
#4322288) to provide permanent genetic identiﬁcation of the
cell lines. https://www.thermoﬁsher.com/order/catalog/product/
4322288
4. Siblingship testing: Due to the de-identifying of embryos the
siblingship of Genea021, Genea022 and Genea023 was tested at
DNA Labs (a subsidiary of Sydney IVF; Sydney, Australia) via analysis
of 15 highly variable loci, 15 variable Y chromosome loci and mito-
chondrial DNA sequences in the D-loop HVRI and HVRII regions.
Pluripotency assessment
1. Immunoﬂuorescence: Passage 14 (11 on feeders, 3 enzymatic); cells
were ﬁxed with formalin and stained with Nanog #560483 1:200;
Oct4 #560217 1:150: Tra1-60 #560121 1:150; SSEA4 #560308
1:200 (all BD Pharmingen). Images were acquired with an IN Cell
Analyser 6000 and quantiﬁed using In Cell Developer Software (GE).
2. Pluritest: Passage 14 (11 on feeders, 3 enzymatic); RNAwas collected
and subjected to a Pluritest, a bioinformatic assay of pluripotency in
human cells based on gene expression proﬁles (Müller et al., 2012).
3. Alkaline Phosphatase: Passage 14; Genea023 grown on feeders were
stained as per manufacturers protocol using the Merck Millipore
Alkaline Phosphatase Detection Kit (SCR004).
4. Teratoma formation: Passage 41; stem cells were received one day
prior to injection. On the day of injection cells were harvested by
manual scraping, washed and resuspended in DMEM/20% KSR for
intramuscular injection of cells into the left inner thigh muscle of
the hind leg. Approximately 1–2 × 106 cells (1 × T25) in 50 μL
were injected per mouse at one site only. Resultant teratomas were
excised, ﬁxed, sectioned and stained for assessment of tissues from
each of the embryonic germ layers.
Sterility testing
1. Mycoplasma: Passage 36; testing was performed at the Victorian
Infectious Diseases Reference Laboratory using Mycoplasma Genus
PCR.
2. Microbial contamination: testing was performed in conjunction with
our QC measures. Cells were thawed and cultured in 7 mL antibiotic
free medium (Genea Biocells M2 medium) for 2–3 days at 37 °C.
A clear solution at ~48–72 h indicated lack of bacterial, fungal
or yeast contamination. Clarity of the solution was assessed by Cell
Production Team.
Veriﬁcation and authentication
Ethics/consents: Karyotyped embryo cells were fully consented for
development of stem cells by all responsible people through an
informed consent process (signed de-identiﬁed consent form can be
provided upon request). Donors have received no payment of otherD16S539 D2S1338 D19S433 vWA TPOX D18S51 D5S818 FGA
11,13 17,24 13,14 14,19 8,9 13,16 11,12 22,24
Table 3
Summary of siblingship testing; de-identiﬁed Genea021, Genea022 and Genea023 share
identical maternal and paternal lines and with variable loci analysis are likely related as
full siblings.
Result
Variable loci analysis SIVF021 and SIVF022 — full sibs inconclusive
SIVF021 and SIVF023 — full sibs practically proven
SIVF022 and SIVF023 — full sibs inconclusive
Y chromosome comparison No mismatches between the lines thus common
paternal lineage
Mitochondrial DNA analysis Identical mitochondrial sequences thus common
maternal line
Interpretation It is likely that all cell lines are related
458 B. Dumevska et al. / Stem Cell Research 16 (2016) 456–459beneﬁts for their donation. Donated embryos originally created by
assisted reproduction technology (ART) for the purpose of procreation.
Embryoswere identiﬁed as unsuitable for implantation, biopsy or freez-
ing due to abnormal development. Embryonic outgrowths were devel-
oped for consented clinical investigation studies. Results of the studies
have been reported back to the patient.
Morphology: The derived stem cell line, Genea023, morphologically
displays adherent monolayer of compact cells in well-deﬁned colonies
with high nuclear to cytoplasmic ratio and prominent nucleoli (Fig. 1A).
Genetic analysis: The cell line has been karyotyped (Fig. 1B, Supple-
mentary Fig. 1) and tested by CGH (Table 1, Supplementary Fig. 2),
which demonstrated 46, X Y karyotype, consistent with original deriva-
tion. Analysis of STR markers showed allele pattern consistent with
male genotype (Table 2, Supplementary Fig. 3). Siblingship analysisFig. 2. Pluripotency validation of Genea023. A) Immunoﬂuorescent staining (10×) of pluripoten
enzymatic). B) Quantitation of expression of pluripotent markers. C) Pluritest pluripotency (le
D) Tri-lineage teratoma formation (passage 41) with (left) cartilage, bone, squamous epithel
mesenchyme.showed Genea021 to be siblings with Genea022 and Genea023
(Table 3, Supplementary Fig. 4).
Disease status: Unaffected.
Pluripotency: GENEA023 is pluripotent by:
1. Alkaline Phosphatase stain positivity (Fig. 1A).
2. Immunoﬂuorescence with 85% Nanog positive, 98% Oct4, 55%
Tra1-60 and 98% SSEA4 positive (Fig. 2A, quantiﬁed in 2B).
3. Pluritest with a Pluripotency score of 42.76 and Novelty score of 1.23
(Fig. 2C).
4. Teratoma formation which contained tissues derived from each of the
embryonic germ layers: endoderm,mesoderm, and ectoderm (Fig. 2D).
Sterility: The cell line is tested and found negative for Mycoplasma
and any visible contamination (Supplementary Fig. 5).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2016.02.012.
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